(Rac)-Modipafant
Product Sizes
5 mg
£ POA
HY-108908-5MG
10 mg
£ POA
HY-108908-10MG
100 mg
£ POA
HY-108908-100MG
25 mg
£ POA
HY-108908-25MG
1 mg
£ POA
HY-108908-1MG
50 mg
£ POA
HY-108908-50MG
10mM/1mL
£ POA
HY-108908-10MM
About this Product
- SKU:
- HY-108908
- Additional Names:
- UK-74505
- CAS Number:
- 122956-68-7
- Extra Details:
- (Rac)-Modipafant (UK-74505) is an orally active; selective; long-acting irreversible platelet activating factor receptor (PAFR) antagonist. (Rac)-Modipafant prevents dengue infection[1][2][3].
- Molecular Weight:
- 605.09
- Purity:
- 98.15
- References:
- [1]O'Connor BJ, et al. Inhibitory effect of UK,74505, a potent and specific oral platelet activating factor (PAF) receptor antagonist, on airway and systemic responses to inhaled PAF in humans. Am J Respir Crit Care Med. 1994;150(1):35-40.|[2]Alabaster VA, et al. UK-74,505, a novel and selective PAF antagonist, exhibits potent and long lasting activity in vivo. Agents Actions Suppl. 1991;34:221-227.|[3]Parry MJ, Alabaster VA, et al. Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity. J Lipid Mediat Cell Signal. 1994;10(3):251-268.|[4]Guerrero AT, et al. The role of PAF/PAFR signaling in zymosan-induced articular inflammatory hyperalgesia [published correction appears in Naunyn Schmiedebergs Arch Pharmacol. 2013 Apr;386(4):351. Zaperlon, Ana C [corrected to Zarpelon, Ana C]]. Naunyn Schmiedebergs Arch Pharmacol. 2013;386(1):51-59.|[5]Souza DG, et al. Essential role of platelet-activating factor receptor in the pathogenesis of Dengue virus infection. Proc Natl Acad Sci U S A. 2009;106(33):14138-14143.
- Research Area:
- Infection; Inflammation/Immunology
- Shipping Conditions:
- Ambient
- Storage Conditions:
- -20[o]C; 3 years; 4[o]C; 2 years (Powder)
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Small Molecules
- Pathway:
- Anti-infection
